Palo Alto – April 7, 2017 – Cooley advised Calithera Biosciences on its $80.5 million shelf-takedown offering of 7,854,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase an additional 1,024,500 shares.
Calithera, which is headquartered in South San Francisco and trades on The NASDAQ Global Select Market as "CALA," is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
Cooley has worked with Calithera since its formation and advised the company on its $80 million IPO in October 2014.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.